Exagen is a life science company based in Vista, California, focused on the accurate diagnosis and monitoring of patients with autoimmune rheumatic diseases. Established in 2002, Exagen offers a range of testing products under its AVISE brand, which are designed to furnish objective information for physicians and patients. These tests facilitate accurate and timely diagnoses, enabling better management of autoimmune rheumatic diseases. Exagen primarily markets its solutions to community rheumatologists, addressing a significant unmet need in the field of rheumatology.
Surefire Medical, located in Westminster, Colorado, was established in 2009 to innovate in the interventional radiology sector. The company specializes in a unique infusion system that facilitates the precise delivery of embolic agents via its advanced catheter design. This system features an expandable tip that collapses during forward flow to preserve blood flow and expands against the vessel wall during reverse flow to minimize reflux. This innovative design aims to significantly reduce damage to healthy tissue, enhancing the effectiveness and safety of interventional procedures.
CareSync is a prominent provider of software and services focused on chronic disease management. The company integrates technology with round-the-clock nursing services to enhance care coordination among patients, families, caregivers, and healthcare providers. CareSync offers comprehensive Chronic Care Management services, along with a software-only option, enabling healthcare practices of any size to comply with billing requirements for chronic care codes. Its certified technology also helps providers achieve Meaningful Use 2 standards for data exchange and timely access to health information. By centralizing records from various providers, CareSync allows for the secure storage and organization of health information, making it easily accessible for caregivers and healthcare professionals. This patient-centered approach empowers individuals with access to their health information and actionable goals, leading to more effective medical appointments and improved health outcomes.
CareSync is a prominent provider of software and services focused on chronic disease management. The company integrates technology with round-the-clock nursing services to enhance care coordination among patients, families, caregivers, and healthcare providers. CareSync offers comprehensive Chronic Care Management services, along with a software-only option, enabling healthcare practices of any size to comply with billing requirements for chronic care codes. Its certified technology also helps providers achieve Meaningful Use 2 standards for data exchange and timely access to health information. By centralizing records from various providers, CareSync allows for the secure storage and organization of health information, making it easily accessible for caregivers and healthcare professionals. This patient-centered approach empowers individuals with access to their health information and actionable goals, leading to more effective medical appointments and improved health outcomes.
OrthoSensor, Inc. is a medical device company based in Dania Beach, Florida, focused on developing orthopedic devices that incorporate advanced sensor technology. The company's flagship product, VERASENSE, is a disposable instrument designed for total knee arthroplasty, providing real-time evidence-based data to surgeons during surgery to aid in soft tissue balancing and implant positioning. Additionally, OrthoSensor offers OrthoLogIQ, a cloud-based data collection system that integrates data from the VERASENSE device with patient demographics and outcomes. The company aims to enhance patient outcomes and reduce treatment costs for musculoskeletal diseases through its innovative products and services. Founded in 2007, OrthoSensor also engages in training and education, as well as clinical and bioengineering research, and markets its solutions through a network of sales representatives across the United States.
CareSync is a prominent provider of software and services focused on chronic disease management. The company integrates technology with round-the-clock nursing services to enhance care coordination among patients, families, caregivers, and healthcare providers. CareSync offers comprehensive Chronic Care Management services, along with a software-only option, enabling healthcare practices of any size to comply with billing requirements for chronic care codes. Its certified technology also helps providers achieve Meaningful Use 2 standards for data exchange and timely access to health information. By centralizing records from various providers, CareSync allows for the secure storage and organization of health information, making it easily accessible for caregivers and healthcare professionals. This patient-centered approach empowers individuals with access to their health information and actionable goals, leading to more effective medical appointments and improved health outcomes.
Exagen is a life science company based in Vista, California, focused on the accurate diagnosis and monitoring of patients with autoimmune rheumatic diseases. Established in 2002, Exagen offers a range of testing products under its AVISE brand, which are designed to furnish objective information for physicians and patients. These tests facilitate accurate and timely diagnoses, enabling better management of autoimmune rheumatic diseases. Exagen primarily markets its solutions to community rheumatologists, addressing a significant unmet need in the field of rheumatology.
Exagen is a life science company based in Vista, California, focused on the accurate diagnosis and monitoring of patients with autoimmune rheumatic diseases. Established in 2002, Exagen offers a range of testing products under its AVISE brand, which are designed to furnish objective information for physicians and patients. These tests facilitate accurate and timely diagnoses, enabling better management of autoimmune rheumatic diseases. Exagen primarily markets its solutions to community rheumatologists, addressing a significant unmet need in the field of rheumatology.
Exagen is a life science company based in Vista, California, focused on the accurate diagnosis and monitoring of patients with autoimmune rheumatic diseases. Established in 2002, Exagen offers a range of testing products under its AVISE brand, which are designed to furnish objective information for physicians and patients. These tests facilitate accurate and timely diagnoses, enabling better management of autoimmune rheumatic diseases. Exagen primarily markets its solutions to community rheumatologists, addressing a significant unmet need in the field of rheumatology.
ESTECH is a privately held medical device manufacturing and distribution company located in San Ramon, California. The company was founded by Arthur and Raymond Bertolero in 1996 with an emphasis on least invasive products for cardiac surgery. ESTECH has worldwide distribution and has consistently attracted goal oriented professionals who represent the brightest minds in the medical device industry. The in-depth professional experience and tireless dedication of the ESTECH Team has allowed the company to achieve rapid and sustained success in this highly competitive environment. ESTECH is proud of each employee from every department and thanks them for their contribution and support.
Exagen is a life science company based in Vista, California, focused on the accurate diagnosis and monitoring of patients with autoimmune rheumatic diseases. Established in 2002, Exagen offers a range of testing products under its AVISE brand, which are designed to furnish objective information for physicians and patients. These tests facilitate accurate and timely diagnoses, enabling better management of autoimmune rheumatic diseases. Exagen primarily markets its solutions to community rheumatologists, addressing a significant unmet need in the field of rheumatology.
Exagen is a life science company based in Vista, California, focused on the accurate diagnosis and monitoring of patients with autoimmune rheumatic diseases. Established in 2002, Exagen offers a range of testing products under its AVISE brand, which are designed to furnish objective information for physicians and patients. These tests facilitate accurate and timely diagnoses, enabling better management of autoimmune rheumatic diseases. Exagen primarily markets its solutions to community rheumatologists, addressing a significant unmet need in the field of rheumatology.
Exagen is a life science company based in Vista, California, focused on the accurate diagnosis and monitoring of patients with autoimmune rheumatic diseases. Established in 2002, Exagen offers a range of testing products under its AVISE brand, which are designed to furnish objective information for physicians and patients. These tests facilitate accurate and timely diagnoses, enabling better management of autoimmune rheumatic diseases. Exagen primarily markets its solutions to community rheumatologists, addressing a significant unmet need in the field of rheumatology.
Exagen is a life science company based in Vista, California, focused on the accurate diagnosis and monitoring of patients with autoimmune rheumatic diseases. Established in 2002, Exagen offers a range of testing products under its AVISE brand, which are designed to furnish objective information for physicians and patients. These tests facilitate accurate and timely diagnoses, enabling better management of autoimmune rheumatic diseases. Exagen primarily markets its solutions to community rheumatologists, addressing a significant unmet need in the field of rheumatology.
ESTECH is a privately held medical device manufacturing and distribution company located in San Ramon, California. The company was founded by Arthur and Raymond Bertolero in 1996 with an emphasis on least invasive products for cardiac surgery. ESTECH has worldwide distribution and has consistently attracted goal oriented professionals who represent the brightest minds in the medical device industry. The in-depth professional experience and tireless dedication of the ESTECH Team has allowed the company to achieve rapid and sustained success in this highly competitive environment. ESTECH is proud of each employee from every department and thanks them for their contribution and support.
BioBehavioral Diagnostics Company manufactures and markets the Quotientâ„¢ ADHD System, a tool that aids in the objective and accurate assessment of ADHD symptoms. They are dedicated to providing physicians, parents and patients with high-value information to guide personalized strategies and to enhance quality of life for patients with ADHD.
Synageva is a biopharmaceutical company dedicated to developing and commercializing novel, next generation and follow on protein therapeutics that leverage the unique competitive advantages of their proprietary Synageva Expression Platform (SEPTM).
Coherex Medical, Inc. specializes in the design, development, and marketing of catheter-based technologies aimed at treating structural heart defects. The company focuses on developing devices for patients with atrial fibrillation who are at risk for stroke, including an innovative closure system for the left atrial appendage (LAA) and a patent foramen ovale (PFO) closure system that promotes tissue in-growth for long-term closure. Founded in 2003 as Proximare, Inc., the company rebranded to Coherex Medical in 2006 and is headquartered in Salt Lake City, Utah. Coherex Medical serves both domestic and international markets, providing crucial treatment options for structural heart conditions. As of 2015, the company operates as a subsidiary of Biosense Webster, Inc.
Vidacare Corporation is a medical device company based in San Antonio, Texas, specializing in intraosseous access devices designed for use in diagnostic, monitoring, and therapeutic applications. The company’s flagship product, the EZ-IO Product System, enables controlled vascular access through the intraosseous route, particularly beneficial in emergency situations where traditional vascular access methods are ineffective. The EZ-IO power driver is engineered to penetrate the intraosseous space using a hollow needle and integrated stylet, ensuring accurate placement. Additionally, the EZ-IO Vascular Access Pack equips emergency medical personnel with the necessary tools to establish vascular access quickly. Vidacare also offers a range of hematology and oncology products, including systems for bone marrow aspiration and biopsy. Its innovations are utilized in various settings, including pre-hospital care, emergency response, and military operations, catering to the needs of healthcare providers in critical situations. Founded in 2001, Vidacare continues to advance intraosseous access technology for the medical community.
Synageva is a biopharmaceutical company dedicated to developing and commercializing novel, next generation and follow on protein therapeutics that leverage the unique competitive advantages of their proprietary Synageva Expression Platform (SEPTM).
Atritech, based in Minneapolis, Minnesota, is a private company founded in 2000 that specializes in developing innovative technologies aimed at preventing strokes related to atrial fibrillation. The company's flagship product, the WATCHMAN Device, is a minimally invasive system designed to close the left atrial appendage, where harmful blood clots can form. This device serves as a permanent alternative to long-term anticoagulation therapy, offering patients a means to reduce their stroke risk associated with non-valvular atrial fibrillation. The WATCHMAN Device has been clinically tested in a large randomized trial comparing its effectiveness to traditional Warfarin therapy. Initially implanted in Germany in 2002 and in the United States in 2003, the device has received CE Mark approval and is available in several international markets, though it is currently designated for investigational use only in the United States.
ALDAGEN is a biopharmaceutical company developing proprietary regenerative cell therapies that target significant unmet medical needs. We have four product candidates in clinical trials. Our most advanced product candidate is ALD-101. We are currently conducting a pivotal Phase 3 clinical trial of ALD-101 to evaluate its efficacy in improving umbilical cord blood, or cord blood, transplants used to treat inherited metabolic diseases in pediatric patients. We are also conducting or supporting Phase 1 or Phase 1/2 clinical trials of three other product candidates ALD--151 to improve cord blood transplants used for the treatment of leukemia; ALD-301 to treat critical limb ischemia; and ALD-201 to treat ischemic heart failure.
Atritech, based in Minneapolis, Minnesota, is a private company founded in 2000 that specializes in developing innovative technologies aimed at preventing strokes related to atrial fibrillation. The company's flagship product, the WATCHMAN Device, is a minimally invasive system designed to close the left atrial appendage, where harmful blood clots can form. This device serves as a permanent alternative to long-term anticoagulation therapy, offering patients a means to reduce their stroke risk associated with non-valvular atrial fibrillation. The WATCHMAN Device has been clinically tested in a large randomized trial comparing its effectiveness to traditional Warfarin therapy. Initially implanted in Germany in 2002 and in the United States in 2003, the device has received CE Mark approval and is available in several international markets, though it is currently designated for investigational use only in the United States.
ALDAGEN is a biopharmaceutical company developing proprietary regenerative cell therapies that target significant unmet medical needs. We have four product candidates in clinical trials. Our most advanced product candidate is ALD-101. We are currently conducting a pivotal Phase 3 clinical trial of ALD-101 to evaluate its efficacy in improving umbilical cord blood, or cord blood, transplants used to treat inherited metabolic diseases in pediatric patients. We are also conducting or supporting Phase 1 or Phase 1/2 clinical trials of three other product candidates ALD--151 to improve cord blood transplants used for the treatment of leukemia; ALD-301 to treat critical limb ischemia; and ALD-201 to treat ischemic heart failure.
Impulse Monitoring specializes in intra-operative neurophysiological monitoring solutions for hospitals and healthcare facilities, enhancing surgical safety during spinal, nerve, and brain surgeries. The company's IONM service provides critical insights into a patient's nervous system, alerting surgeons to potential risks and enabling informed decision-making. This technology is applicable across various surgical fields, including neurosurgery, orthopedic surgery, vascular surgery, cardiac surgery, and otolaryngology. By delivering real-time data on the condition of neural structures, Impulse Monitoring aims to reduce surgical risks and improve patient outcomes. The company is based in Columbia, Maryland.
BioBehavioral Diagnostics Company manufactures and markets the Quotientâ„¢ ADHD System, a tool that aids in the objective and accurate assessment of ADHD symptoms. They are dedicated to providing physicians, parents and patients with high-value information to guide personalized strategies and to enhance quality of life for patients with ADHD.
Adiana, Inc. engages in the development and testing of transcervical sterilization system for permanent birth control. It develops Complete TCS, which consists of a radiofrequency generator, delivery catheter, and implantable matrix. The company was founded in 1997 and is based in Redwood City, California. As of March 16, 2007, Adiana, Inc. is a subsidiary of CYTYC Corp.
Exagen is a life science company based in Vista, California, focused on the accurate diagnosis and monitoring of patients with autoimmune rheumatic diseases. Established in 2002, Exagen offers a range of testing products under its AVISE brand, which are designed to furnish objective information for physicians and patients. These tests facilitate accurate and timely diagnoses, enabling better management of autoimmune rheumatic diseases. Exagen primarily markets its solutions to community rheumatologists, addressing a significant unmet need in the field of rheumatology.
Myocor is a medical company based in Minnesota that specializes in developing and distributing therapeutic devices aimed at treating mitral valve insufficiency and congestive heart failure. Founded in 1996, Myocor focuses on innovations that enhance cardiac function and improve clinical outcomes for patients with late-stage heart failure. One of its key products, Coapsys, employs a system of pads and a tensioned string inserted through the heart to reshape an enlarged heart and optimize the performance of a leaky mitral valve. Through its technologies, Myocor aims to address the challenges associated with heart failure and provide effective treatment options for affected individuals.
Valeo Medical
Series B in 2004
Valeo Medical, Inc., a life sciences company, develops a non-invasive diagnostic blood test for endometriosis. The company was founded in 2003 and is based in Burlington, Massachusetts. Valeo raised money as part of the Discovery Life Sciences fund which was partly funded by the Nashville Capital Network.
BioRexis has developed proprietary protein engineering technologies based upon human transferrin that provide novel therapeutic agents with longer duration of action than synthetic peptides. In addition to reducing dosing frequency, these technologies have the potential to substantially improve patient tolerability. This new platform supports Pfizer’s commitment to develop novel protein therapeutic agents.
TransMolecular, Inc. is a neuroscience biotechnology firm focused on discovering and developing innovative drugs for diagnosing and treating central nervous system diseases, particularly cancer and pain, where current treatment options are limited. Founded in 1996 and based in Birmingham, Alabama, the company has established robust technology platforms that support its product discovery and development efforts. It has received significant funding, including $9.6 million from venture capital sources and $1 million in Small Business Incentive Research grants from the National Institutes of Health. TransMolecular possesses over 25 patents and patent applications to safeguard its intellectual property and has exclusive licensing agreements with the University of Alabama at Birmingham Research Foundation and Yale University for its specialized technologies. The management team brings more than 75 years of combined experience in healthcare, pharmaceutical development, and related fields, underscoring the company’s commitment to creating safe and effective treatments for patients suffering from serious medical conditions.
Exagen is a life science company based in Vista, California, focused on the accurate diagnosis and monitoring of patients with autoimmune rheumatic diseases. Established in 2002, Exagen offers a range of testing products under its AVISE brand, which are designed to furnish objective information for physicians and patients. These tests facilitate accurate and timely diagnoses, enabling better management of autoimmune rheumatic diseases. Exagen primarily markets its solutions to community rheumatologists, addressing a significant unmet need in the field of rheumatology.
Valeo Medical
Series A in 2003
Valeo Medical, Inc., a life sciences company, develops a non-invasive diagnostic blood test for endometriosis. The company was founded in 2003 and is based in Burlington, Massachusetts. Valeo raised money as part of the Discovery Life Sciences fund which was partly funded by the Nashville Capital Network.
BioRexis has developed proprietary protein engineering technologies based upon human transferrin that provide novel therapeutic agents with longer duration of action than synthetic peptides. In addition to reducing dosing frequency, these technologies have the potential to substantially improve patient tolerability. This new platform supports Pfizer’s commitment to develop novel protein therapeutic agents.
TransMolecular, Inc. is a neuroscience biotechnology firm focused on discovering and developing innovative drugs for diagnosing and treating central nervous system diseases, particularly cancer and pain, where current treatment options are limited. Founded in 1996 and based in Birmingham, Alabama, the company has established robust technology platforms that support its product discovery and development efforts. It has received significant funding, including $9.6 million from venture capital sources and $1 million in Small Business Incentive Research grants from the National Institutes of Health. TransMolecular possesses over 25 patents and patent applications to safeguard its intellectual property and has exclusive licensing agreements with the University of Alabama at Birmingham Research Foundation and Yale University for its specialized technologies. The management team brings more than 75 years of combined experience in healthcare, pharmaceutical development, and related fields, underscoring the company’s commitment to creating safe and effective treatments for patients suffering from serious medical conditions.
SupplyPro®'s inventory management systems for the Maintenance, Repair and Operations environment control inventory from point-of-use to replenishment. Our web-based "inventory management" units maintain an extremely cost-effective just-in-time inventory, eliminating critical stock-outs. When supplies reach a pre-determined "low", our systems automatically reorder from your supplier.
AmericasDoctor, a unique pharmaceutical services company, combines and integrates leading physician researchers, strategic marketing and consumer outreach capabilities, distinguished hospitals and advanced Internet resources to assist the pharmaceutical industry in developing, positioning and promoting its products. AmericasDoctor was formed in January 2000 from a merger between Affiliated Research Centers (ARC) and AmericasDoctor.com. AmericasDoctor Research Services (formerly ARC) provides investigative site and patient recruitment capabilities through its 150 investigative sites operating in 37 states in the U.S. and five provinces in Canada. Currently, AmericasDoctor is conducting over 550 studies in urology, rheumatology, pulmonology and respiratory disease, endocrinology, cardiology, women’s health, gastroenterology and neuroscience. AmericasDoctor Web Services provides information to consumers in response to health information inquiries. It is the only medical/health Internet site to offer private, real-time, one-on-one chats with board-certified, board-eligible physicians 24 hours a day, seven days a week at no cost to the consumer. This site is sponsored by over 100 leading U.S. hospitals. AmericasDoctor supports the combined efforts of the medical community and pharmaceutical industry to improve the lives of people suffering from chronic illnesses. AmericasDoctor provides the vital link between the patient, the medical expert and the development of new therapies. To the consumer, this means enhanced lives, the empowerment to manage their medical situations and the possibility of improved treatment efficacy. For pharmaceutical companies, this means unique approaches in defining, developing and expediting new products and solutions. AmericasDoctor is a privately held company with a strategic vision to provide a new generation of pharmaceutical services integrating information, marketing and research resources to help create tomorrow’s medicine.
Centromine
Venture Round in 1999
Centromine offers a browser-based, internet-accessed, enterprise-wide software applications and services for the health care market. Its applications allow behavioral health care programs and providers to manage the delivery and associated quality and cost of services completely over the internet.
TransMolecular, Inc. is a neuroscience biotechnology firm focused on discovering and developing innovative drugs for diagnosing and treating central nervous system diseases, particularly cancer and pain, where current treatment options are limited. Founded in 1996 and based in Birmingham, Alabama, the company has established robust technology platforms that support its product discovery and development efforts. It has received significant funding, including $9.6 million from venture capital sources and $1 million in Small Business Incentive Research grants from the National Institutes of Health. TransMolecular possesses over 25 patents and patent applications to safeguard its intellectual property and has exclusive licensing agreements with the University of Alabama at Birmingham Research Foundation and Yale University for its specialized technologies. The management team brings more than 75 years of combined experience in healthcare, pharmaceutical development, and related fields, underscoring the company’s commitment to creating safe and effective treatments for patients suffering from serious medical conditions.